SUBSCRIBE
SUBSCRIBE

Phase 2

Drug Development
Biopharma Update on the Novel Coronavirus: May 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
May 8, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Moderna Moves into Phase II Testing of COVID-19 Vaccine Candidate
Stéphane Bancel, Moderna’s chief executive officer, said the Phase II study is a crucial step in advancing the vaccine candidate as the company looks toward the goal of moving into Phase III.
May 7, 2020
 · 
2 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: May 7
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
May 7, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
May 6, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Sanofi and Regeneron’s Libtayo Shows Benefit in Basal Cell Carcinoma
Sanofi and Regeneron are focusing on basal cell carcinoma treatment and their drug Libtayo is showing good results. The companies expect to make regulatory submissions this year.
May 5, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
May 5, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
May 4, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biotech Professionals Express Fears…and Hope, During Pandemic
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
May 1, 2020
 · 
5 min read
 · 
Gail Dutton
Bio NC
Clinical Catch-Up: April 27-May 1
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
May 1, 2020
 · 
11 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
May 1, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Press Releases
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
 · 
4 min read
Press Releases
Noema Pharma to Present Phase 2a Results for Cendifensine in Vasomotor Symptoms (Hot Flashes) Due to Menopause at the 2026 ACOG Annual Clinical & Scientific Meeting
May 1, 2026
 · 
2 min read
Press Releases
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
May 1, 2026
 · 
6 min read
Press Releases
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
May 1, 2026
 · 
5 min read
Press Releases
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
May 1, 2026
 · 
7 min read
Press Releases
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
April 30, 2026
 · 
6 min read
Press Releases
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
April 30, 2026
 · 
9 min read
Press Releases
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
April 30, 2026
 · 
3 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
April 30, 2026
 · 
7 min read
Press Releases
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
April 30, 2026
 · 
5 min read
Press Releases
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
April 30, 2026
 · 
7 min read
Press Releases
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
April 30, 2026
 · 
7 min read
Press Releases
Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis
April 30, 2026
 · 
4 min read
Press Releases
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
April 30, 2026
 · 
6 min read
Press Releases
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 30, 2026
 · 
13 min read
Press Releases
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer’s Disease
April 30, 2026
 · 
6 min read
Press Releases
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
April 30, 2026
 · 
5 min read
Press Releases
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
April 29, 2026
 · 
10 min read
Press Releases
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
April 29, 2026
 · 
9 min read
Press Releases
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy’s Annual Meeting
April 29, 2026
 · 
2 min read
Load More